Underactive Urinary Bladder

Symptom of underactive detrusor muscle of the URINARY BLADDER that contracts with abnormally reduced strength or duration resulting in an incomplete and/or prolonged bladder emptying.

Also Known As:

Urinary Bladder, Underactive; Bladder, Underactive; Detrusor Underactivity; Hypotonic Bladder; Underactive Bladder; Underactive Detrusor; Underactive Detrusor Function; Bladder, Hypotonic; Detrusor Function, Underactive; Detrusor, Underactive; Hypotonic Bladders; Underactive Bladders; Underactive Detrusor Functions; Underactive Detrusors; Underactive Urinary Bladders; Underactivity, Detrusor

Networked: 197 relevant articles (29 outcomes, 33 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Urinary Bladder Neck Obstruction (Bladder Neck Obstruction)
2.	Overactive Urinary Bladder (Overactive Bladder)
3.	Lower Urinary Tract Symptoms
4.	Nocturia
5.	Stroke (Strokes)

Experts

1.	Kuo, Hann-Chorng: 13 articles (05/2020 - 03/2003)
2.	Chancellor, Michael B: 10 articles (04/2019 - 11/2008)
3.	Tyagi, Pradeep: 8 articles (01/2022 - 01/2014)
4.	Yoshimura, Naoki: 8 articles (01/2022 - 01/2014)
5.	Obara, Keisuke: 6 articles (01/2021 - 01/2017)
6.	Tanaka, Yoshio: 6 articles (01/2021 - 01/2017)
7.	Balzarro, Matteo: 5 articles (01/2022 - 01/2019)
8.	Park, Juhyun: 5 articles (12/2021 - 01/2016)
9.	Okada, Hiroki: 5 articles (01/2020 - 11/2014)
10.	Chuang, Yao-Chi: 5 articles (04/2019 - 01/2014)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Underactive Urinary Bladder:

1.	Type A Botulinum Toxins (Botox)FDA Link 12/13/2016 - "The results were similar between the dysfunctional voiding and detrusor underactivity subgroups; however, a significant reduction in detrusor voiding pressure was only observed in dysfunctional voiding patients who received onabotulinumtoxinA. " 03/01/2003 - "Botulinum A toxin at a dose of 50 U was effective in reducing urethral sphincter resistance among our patients with detrusor underactivity and difficult urination." 01/01/2019 - "The aim of the present study was to analyze treatment outcomes and identify videourodynamic factors predictive of successful urethral onabotulinumtoxinA treatment of neurogenic and non-neurogenic detrusor underactivity (DU). " 07/05/2019 - "The aim of this retrospective study was to evaluate the clinical efficacy and safety of botulinum toxin type A (BTX-A) injection into the urethral sphincter to treat patients with underactive bladder (UAB). " 07/05/2019 - "Efficacy and safety of botulinum toxin a injection into urethral sphincter for underactive bladder."
2.	Cholinergic Agents (Cholinergics)IBA 02/01/2004 - "Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor." 12/01/2014 - "The efficacy of cholinergic drugs for reduction of post-voiding residual volume (PVR) in patients with underactive bladder is still controversial. " 02/01/2004 - "The aim of the present study was to compare the effectiveness of a cholinergic drug, an alpha-blocker and combinations of the two for the treatment of underactive detrusor. " 12/01/2014 - "Patients with underactive bladder treated for more than two months with cholinergic drugs, which were later discontinued, were extracted retrospectively based on their charts. " 02/01/2004 - "Combination therapy with a cholinergic drug and an alpha-blocker appears to be more useful than monotherapy for the treatment of underactive detrusor."
3.	incobotulinumtoxinA FDA Link 06/16/2023 - "Correction: Tsai et al. The Efficacy of Transvaginal Ultrasound-Guided BoNT-A External Sphincter Injection in Female Patients with Underactive Bladder. " 01/01/2023 - "The Efficacy of Transvaginal Ultrasound-Guided BoNT-A External Sphincter Injection in Female Patients with Underactive Bladder." 01/01/2023 - "This study retrospectively analyzed patients with refractory voiding dysfunction, including detrusor underactivity (DU), dysfunctional voiding (DV), and poor relaxation of the external sphincter (PRES) who received the urethral sphincter 100 U BoNT-A injection. " 01/01/2023 - "Our results demonstrated that a transvaginal ultrasound-guided BoNT-A injection was efficacious and safe in the treatment of underactive bladder." 12/15/2022 - "Patients who received urethral sphincter BoNT-A injection for refractory voiding dysfunction due to detrusor underactivity (DU) or urethral sphincter dysfunction were retrospectively reviewed. "
4.	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/01/2021 - "This study was performed to investigate whether human mesenchymal stem cells (hMSCs) were capable of restoring bladder contractility in rats with underactive bladder due to bladder outlet obstruction (BOO) and enhancing their effects by overexpressing hepatocyte growth factor (HGF) in hMSCs. " 01/01/2022 - "Correction: Improved bladder contractility after transplantation of human mesenchymal stem cells overexpressing hepatocyte growth factor into underactive bladder from bladder outlet obstruction models of rats." 01/01/2021 - "Improved bladder contractility after transplantation of human mesenchymal stem cells overexpressing hepatocyte growth factor into underactive bladder from bladder outlet obstruction models of rats."
5.	tac-302IBA 01/01/2018 - "TAC-302 improved storage and voiding dysfunctions by improving bladder denervation and detrusor underactivity even when the treatment was started after storage and voiding dysfunctions had already occurred." 11/01/2022 - "Efficacy of TAC-302 for patients with detrusor underactivity and overactive bladder: a randomized, double-blind, placebo-controlled phase 2 study." 11/01/2022 - "This multicenter, randomized, double-blind, placebo-controlled phase 2 study evaluated the efficacy and safety of TAC-302, a novel drug that restores neurite outgrowth, in patients with detrusor underactivity (DU) and overactive bladder (OAB). "
6.	Cholinergic Antagonists (Anticholinergics)IBA 10/01/2012 - "Based on current studies, we conclude that patients with detrusor underactivity should be managed with clean intermittent catheterization or indwelling Foley catheter, while timed voiding with or without anticholinergic therapy may be an effective treatment for patients with detrusor overactivity after stroke." 07/01/2017 - "The search included a combination of the following terms, PPI, detrusor overactivity (DO), detrusor underactivity (DU), impaired compliance, anticholinergic, onabotulinumtoxinA (Botox®) and sacral neuromodulation (SNM). "
7.	ParasympathomimeticsIBA 01/01/2022 - "Overall, it is not possible to draw clear evidence-based conclusions from the current literature, presenting the use of parasympathomimetics for treating underactive bladder as a key area that requires future well-controlled clinical trials." 01/01/2022 - "The aim of this review was to assess the effectiveness, both benefits and harms, of using parasympathomimetics for the treatment of underactive bladder. " 01/01/2022 - "The effectiveness of parasympathomimetics for treating underactive bladder: A systematic review and meta-analysis." 04/01/2007 - "Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based?" 01/01/2022 - "Biological rationale suggests that parasympathomimetics (cholinergic receptor stimulating agents) could be beneficial for patients with underactive bladder. "
8.	Muscarinic M3 ReceptorIBA 01/01/2022 - "The aim of this study is to evaluate safety and efficacy of ASP8302, a novel positive allosteric modulator for the muscarinic M3 receptor (M3-PAM), in patients with underactive bladder (UAB). "
9.	Serotonin (5 Hydroxytryptamine)IBA 09/01/2019 - "Underactive bladder in aging rats is associated with a reduced number of serotonin-expressing cells in the urethra and is improved by serotonin application to the urethra." 09/01/2019 - "The aim of this study was to determine whether aging-related detrusor underactivity (DU) involves a decrease in 5-hydroxytryptamine (5-HT-positive)-expressing urethral cells and whether 5-HT stimulation of urethral sensory fibers improves detrusor function. "
10.	ONO-8055IBA 01/01/2018 - "ONO-8055 was effective at an extremely low dose (0.01 mg/kg, po, bid) in rats, and dose-dependently improved voiding dysfunction in a monkey model of underactive bladder (UAB). " 08/01/2016 - "Thus, the novel EP2 and EP3 receptor dual agonist ONO-8055 has the potential to improve neurogenic underactive bladder." 05/01/2018 - "Effects of an EP2 and EP3 Receptor Dual Agonist, ONO-8055, on a Radical Hysterectomy-Induced Underactive Bladder Model in Monkeys." 08/01/2016 - "Promising Effects of a Novel EP2 and EP3 Receptor Dual Agonist, ONO-8055, on Neurogenic Underactive Bladder in a Rat Lumbar Canal Stenosis Model." 05/01/2018 - "The objective was to develop an underactive bladder (UAB) model in primates and to evaluate the potential of prostanoid EP2 and EP3 receptor dual agonist ONO-8055 to become a therapeutic agent for UAB. "

Therapies and Procedures

1.	Transurethral Resection of Prostate (TURP) 03/24/2017 - "Several recent studies have demonstrated that the surgical management of BPH in patients with detrusor underactivity (DU) can effectively improve voiding symptoms, but comparative data on the efficacy of HoLEP and TURP are insufficient. " 05/01/2021 - "To investigate the effect of detrusor underactivity on the efficacy of TURP in patients with benign prostate obstruction. " 05/01/2021 - "Detrusor underactivity influences the efficacy of TURP in patients with BPO." 11/01/2020 - "The aim of the study was to evaluate the transurethral resection of the prostate (TURP) outcomes of unobstructed patients with detrusor underactivity (DUA), comparing the surgical results between obstructed and unobstructed males with concomitant DUA, at midterm follow-up. " 01/01/2019 - "The aim of this study is to investigate the treatment outcome in men with detrusor underactivity (DU) and voiding dysfunction who underwent transurethral resection or incision of the prostate (TURP or TUIP). "
2.	Solid-State Lasers 10/01/2018 - "Re: Long-Term Efficacy of Holmium Laser Enucleation of the Prostate in Patients with Detrusor Underactivity or Acontractility." 10/01/2017 - "Re: Long-Term Efficacy of Holmium Laser Enucleation of the Prostate in Patients with Detrusor Underactivity or Acontractility." 11/01/2016 - "Long-term Efficacy of Holmium Laser Enucleation of the Prostate in Patients With Detrusor Underactivity or Acontractility." 01/01/2018 - "Can preoperative detrusor underactivity influence surgical outcomes of 120 W HPS vaporization of the prostate (PVP) or holmium laser enucleation of the prostate (HoLEP)? " 03/24/2017 - "Comparison of Surgical Outcomes Between Holmium Laser Enucleation and Transurethral Resection of the Prostate in Patients With Detrusor Underactivity."
3.	Therapeutics 01/01/2016 - "Intravesical therapy also opens up novel therapeutic targets with improved efficacy and safety for underactive bladder." 06/01/2023 - "The urodynamic study resulted in a detrusor underactivity, with a mean period for urination recovery of 4.5 weeks, regardless of therapies. " 01/01/2018 - "This study provides an opportunity to develop a novel neuromodulation therapy for underactive bladder using SNS." 03/01/2015 - "We conducted the first-regenerative medicine cellular therapy for underactive bladder (UAB) in an FDA-approved, compassionate-use IND trial to evaluate treatment safety and potential clinical efficacy of autologous muscle-derived stem cells (AMDC) on a patient with UAB. " 01/01/2023 - "Autologous adipose-derived mesenchymal stem cell therapy reverses detrusor underactivity: open clinical trial."
4.	Transplantation 01/01/2022 - "Correction: Improved bladder contractility after transplantation of human mesenchymal stem cells overexpressing hepatocyte growth factor into underactive bladder from bladder outlet obstruction models of rats." 01/01/2021 - "Improved bladder contractility after transplantation of human mesenchymal stem cells overexpressing hepatocyte growth factor into underactive bladder from bladder outlet obstruction models of rats."
5.	Extracorporeal Shockwave Therapy 05/01/2023 - "Bladder shock wave therapy was studied in this randomized, double-blind, placebo-controlled study in patients with inadequate bladder emptying (underactive bladder). " 04/01/2019 - "To investigate the long-term functional change of cryoinjury-induced detrusor underactivity (DU) and the therapeutic potential of repeated low-energy shock wave therapy (LESW). " 04/01/2019 - "Long-term functional change of cryoinjury-induced detrusor underactivity and effects of extracorporeal shock wave therapy in a rat model." 01/01/2018 - "Urodynamic and molecular characteristics of detrusor underactivity in a rat cryoinjury model and effects of low energy shock wave therapy." 05/11/2023 - "Prospective, Randomized, Double-blind, Placebo-controlled, Pilot Study of Extracorporeal Shock Wave Therapy for Detrusor Underactivity/Underactive Bladder. "